Articles focusing on dual-targeting antibody designs, from structure optimization to clinical applications.
A new generation of biotech companies is rapidly advancing the antibody landscape, fueled by strong early-stage funding and a focus on differentiated therapeutic strategies. Across modalities, from bispecific antibodies and ADCs to single-domain antibodies, shuttle systems, and half-life extension, these emerging players are not only expanding the scope of what antibodies can target, but also how they function in complex disease settings.
Bispecifics vs. monoclonals: what’s the difference? Biointron outlines structural contrasts and therapeutic applications of each format.
Explore how bispecific antibodies (BsAbs) transform in vivo research by enhancing oncology, immunotherapy, and drug development through dual-targeting precision.
Bispecific ADCs advance oncology. Biointron shows how dual-targeted antibody-drug conjugates improve precision, efficacy, and patient outcomes in cancer treatment.
Bispecific antibodies are transforming medicine. Biointron highlights their design, therapeutic applications, and development pathways for next-generation therapies.
Learn about bispecific antibodies (bsAbs), their history, advantages over monoclonal antibodies, and popular engineering formats like knobs-into-holes and BiTE.
Biointron delivers advanced bispecific antibody production with over 260 proven formats, offering rapid expression, scalable solutions, and trusted CRO expertise for therapeutic development.
Discover advancements in antibody engineering, from bispecific formats to Fc optimization and humanization, driving innovation in next-generation therapeutic antibody development.
You can also contact us on the Scientist and Science Exchange marketplaces.